First, we treated mice carrying subcutaneous OCI-AML2 tumors at the end of the treatment with PBS as depicted in Fig. 2F. We injected them i.p. with nanocarriers complexed with Cy5-labeled DNMT3A-siRNA, prepared the tumor and different organs 24 h after injection (Additional file 1: Figure S6 A and B) and subjected them to ex vivo-fluorescence imaging. The gene discussed is DNMT3A; the disease is neoplasm.